LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Back to previous search Search history
Advanced search

Your last searches

  1. AU="Klas Bratteby"
  2. AU="Kim, Sae-Hoon"
  3. AU=Spivak Jerry L
  4. AU="Joel, Anjana"
  5. AU="Hill, William"
  6. AU="Ken M. Cadigan"
  7. AU="Lee, Hyun-Shik"
  8. AU="Martini, Denise"
  9. AU=Aziz Noreen M
  10. AU="Ho, Tony"
  11. AU=Barzilay Joshua I.
  12. AU="Ishizaka, Alessio"
  13. AU="Chao, Pei-Dawn Lee"
  14. AU="Rosa Gouveia"

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: Fully Automated GMP-Compliant Synthesis of [ 18 F]FE-PE2I

    Klas Bratteby / Charlotte Lund Denholt / Szabolcs Lehel / Ida Nymann Petersen / Jacob Madsen / Maria Erlandsson / Tomas Ohlsson / Matthias Manfred Herth / Nic Gillings

    Pharmaceuticals, Vol 14, Iss 601, p

    2021  Volume 601

    Abstract: In the struggle to understand and accurately diagnose Parkinson′s disease, radiopharmaceuticals and medical imaging techniques have played a major role. By being able to image and quantify the dopamine transporter density, noninvasive diagnostic imaging ... ...

    Abstract In the struggle to understand and accurately diagnose Parkinson′s disease, radiopharmaceuticals and medical imaging techniques have played a major role. By being able to image and quantify the dopamine transporter density, noninvasive diagnostic imaging has become the gold standard. In the shift from the first generation of SPECT tracers, the fluorine-18-labeled tracer [ 18 F]FE-PE2I has emerged as the agent of choice for many physicians. However, implementing suitable synthesis for the production of [ 18 F]FE-PE2I has proved more challenging than expected. Through a thorough analysis of the relevant factors affecting the final radiochemical yield, we were able to implement high-yielding fully automated GMP-compliant synthesis of [ 18 F]FE-PE2I on a Synthera ® + platform. By reaching RCYs up to 62%, it allowed us to isolate 25 GBq of the formulated product, and an optimized formulation resulted in the shelf life of 6 h, satisfying the increased demand for this radiopharmaceutical.
    Keywords [ 18 F]FE-PE2I ; radiochemistry ; fluorine-18 ; automation ; GMP ; Medicine ; R ; Pharmacy and materia medica ; RS1-441
    Subject code 333
    Language English
    Publishing date 2021-06-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  2. Article ; Online: The α-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases

    Ruben Smith / Francesca Capotosti / Martin Schain / Tomas Ohlsson / Efthymia Vokali / Jerome Molette / Tanja Touilloux / Valerie Hliva / Ioannis K. Dimitrakopoulos / Andreas Puschmann / Jonas Jögi / Per Svenningsson / Mattias Andréasson / Christine Sandiego / David S. Russell / Patricia Miranda-Azpiazu / Christer Halldin / Erik Stomrud / Sara Hall /
    Klas Bratteby / Elina Tampio L’Estrade / Ruth Luthi-Carter / Andrea Pfeifer / Marie Kosco-Vilbois / Johannes Streffer / Oskar Hansson

    Nature Communications, Vol 14, Iss 1, Pp 1-

    2023  Volume 12

    Abstract: Abstract A positron emission tomography (PET) tracer detecting α-synuclein pathology will improve the diagnosis, and ultimately the treatment of α-synuclein-related diseases. Here we show that the PET ligand, [18F]ACI-12589, displays good in vitro ... ...

    Abstract Abstract A positron emission tomography (PET) tracer detecting α-synuclein pathology will improve the diagnosis, and ultimately the treatment of α-synuclein-related diseases. Here we show that the PET ligand, [18F]ACI-12589, displays good in vitro affinity and specificity for pathological α-synuclein in tissues from patients with different α-synuclein-related disorders including Parkinson’s disease (PD) and Multiple-System Atrophy (MSA) using autoradiography and radiobinding techniques. In the initial clinical evaluation we include 23 participants with α-synuclein related disorders, 11 with other neurodegenerative disorders and eight controls. In vivo [18F]ACI-12589 demonstrates clear binding in the cerebellar white matter and middle cerebellar peduncles of MSA patients, regions known to be highly affected by α-synuclein pathology, but shows limited binding in PD. The binding statistically separates MSA patients from healthy controls and subjects with other neurodegenerative disorders, including other synucleinopathies. Our results indicate that α-synuclein pathology in MSA can be identified using [18F]ACI-12589 PET imaging, potentially improving the diagnostic work-up of MSA and allowing for detection of drug target engagement in vivo of novel α-synuclein targeting therapies.
    Keywords Science ; Q
    Subject code 610
    Language English
    Publishing date 2023-10-01T00:00:00Z
    Publisher Nature Portfolio
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top